{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:46:23Z","timestamp":1782794783406,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate a case of hepatitis B virus reactivation (HBV-R) in a post-lymphoma patient with renal transplantation and long-term maintenance hemodialysis (MHD), and to explore prevention strategies for high-risk populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient records were reviewed for dialysis history, HBV markers, and liver function. Environmental sampling was conducted, and a multidisciplinary team established individualized management as well as optimized screening and vaccination strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The patient had undergone maintenance hemodialysis since February 2023 with stable hepatitis B virus (HBV) serology. In March 2024, hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA tested positive. The patient had received intermittent chemotherapy and rituximab at another hospital during dialysis. Following reactivation, the patient was transferred to dedicated dialysis equipment with isolation nursing care, strict infection control measures, and environmental monitoring. A multidisciplinary team refined high-risk patient screening and reinforced vaccination programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Hemodialysis patients under prolonged immunosuppression face elevated HBV reactivation risk. Early identification and risk-based management are essential to reduce adverse impacts on patient safety and healthcare quality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1808087","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:25:49Z","timestamp":1782793549000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Hepatitis B virus reactivation following rituximab therapy in a patient receiving maintenance hemodialysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Ruocheng","family":"Luo","sequence":"first","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Department of Infection Control, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Infection Control, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaihong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infection Control, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infection Control, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5009\/gnl210551","article-title":"Risk of hepatitis B virus (HBV) reactivation in HBsAg-negative, anti-HBc-negative patients receiving rituximab for autoimmune diseases in HBV endemic areas","volume":"17","author":"Lan","year":"2023","journal-title":"Gut Liver"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1097\/MEG.0000000000000689","article-title":"Improving testing for hepatitis B before treatment with rituximab","volume":"28","author":"Dyson","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1111\/jgh.16725","article-title":"Rituximab carries high risks of hepatitis B virus reactivation in hematologic and rheumatic patients with chronic or resolved hepatitis B","volume":"39","author":"Hou","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e67722","DOI":"10.7759\/cureus.67722","article-title":"Seroprevalence and seroconversion of hepatitis B and C viruses in patients undergoing hemodialysis: a cross-sectional study","volume":"16","author":"Tayal","year":"2024","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1053\/j.ajkd.2016.03.424","article-title":"Hepatitis B reverse seroconversion and transmission in a hemodialysis center: a public health investigation and case report","volume":"68","author":"Rhea","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e0251570","DOI":"10.1371\/journal.pone.0251570","article-title":"The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: a systematic review and meta-analysis","volume":"16","author":"Adane","year":"2021","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1080\/10428194.2021.1948034","article-title":"Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab","volume":"62","author":"Pei","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.dld.2016.08.113","article-title":"High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphoma patients treated with rituximab-based chemotherapy","volume":"48","author":"Castelli","year":"2016","journal-title":"Dig Liver Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e28549","DOI":"10.1002\/jmv.28549","article-title":"HBsAg(\u2212)\/HBsAb(\u2212)\/HBeAg(\u2212)\/HBeAb(+)\/HBcAb(+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab-based immunochemotherapy","volume":"95","author":"Shui","year":"2023","journal-title":"J Med Virol"},{"key":"ref10","first-page":"831","article-title":"Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis","volume":"35","author":"Tien","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/s41598-020-59406-4","article-title":"Moderate risk of hepatitis B virus reactivation in HBsAg(\u2212)\/HBcAb(+) carriers receiving rituximab for rheumatoid arthritis","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ndt\/gfw455","article-title":"Rituximab and hepatitis B reactivation in HBsAg-negative\/anti-HBc-positive kidney transplant recipients","volume":"32","author":"Lee","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/TP.0000000000001870","article-title":"Incidence of hepatitis B viral reactivation after kidney transplantation with low-dose rituximab administration","volume":"102","author":"Masutani","year":"2018","journal-title":"Transplantation"},{"key":"ref14","volume-title":"Standard Operating Procedures for Blood Purification (2021 Edition)","year":"2021"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2152\/jmi.66.148","article-title":"Bacterial contamination of hemodialysis devices in hospital dialysis wards","volume":"66","author":"Shimohata","year":"2019","journal-title":"J Med Investig"},{"key":"ref16","volume-title":"Regulation of Disinfection Technique in Healthcare Settings (WS\/T 367\u20132012)","year":"2012"},{"key":"ref17","first-page":"2703","article-title":"Link management of hospital infection prevention and control in hemodialysis","volume":"23","author":"Ding","year":"2013","journal-title":"Chin J Nosocomiol"},{"key":"ref18","volume-title":"Dialysis Circuit Disinfectant","year":"2021"},{"key":"ref19","volume-title":"Pharmacopoeia of the People's Republic of China","year":"2020"},{"key":"ref20","first-page":"2161","article-title":"Necessity of dedicated hemodialysis for patients with infectious diseases","volume":"28","author":"Peng","year":"2018","journal-title":"Chin J Nosocomiol."},{"key":"ref21","first-page":"1548","article-title":"Logistic regression analysis of risk factors for hepatitis C virus infection in maintenance dialysis patients","volume":"27","author":"Hua","year":"2017","journal-title":"Chin J Nosocomiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10389-010-0366-2","article-title":"Epidemiology and risk factors of HCV infection among hemodialysis patients in countries of the eastern Mediterranean regional office of WHO (EMRO): a quantitative review of literature","volume":"19","author":"Alavian","year":"2011","journal-title":"J Public Health"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.12998\/wjcc.v10.i1.12","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis","volume":"10","author":"Wu","year":"2022","journal-title":"World J Clin Cases"},{"key":"ref24","first-page":"449","article-title":"Progress in diagnosis and treatment of hepatitis B virus reactivation induced by antineoplastic agents","volume":"39","author":"Cai","year":"2022","journal-title":"J Clin Intern Med"},{"key":"ref25","first-page":"1","article-title":"Chinese Medical Doctor Association; National Clinical Research Center for Infectious Diseases. Expert consensus on whole-population management of hepatitis B","volume":"17","year":"2023","journal-title":"Chin J Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/hepr.12439","article-title":"Immunobiology of hepatitis B virus infection","volume":"45","author":"Isogawa","year":"2015","journal-title":"Hepatol Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1478-3231.2008.01941.x","article-title":"Natural history of chronic hepatitis B virus infection and long-term outcome under treatment","volume":"29","author":"Liaw","year":"2009","journal-title":"Liver Int"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/hep4.1238","article-title":"Preventing hepatitis B reactivation during anti-CD20 antibody treatment in the veterans health administration","volume":"2","author":"Bullard","year":"2018","journal-title":"Hepatol Commun"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/jmv.25540","article-title":"Validity of administrative database detection of previously resolved hepatitis B virus in Japan","volume":"91","author":"Imai","year":"2019","journal-title":"J Med Virol"},{"key":"ref31","first-page":"712","article-title":"Expert recommendations on hepatitis B vaccination in adults","volume":"32","year":"2024","journal-title":"Chin J Hepatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1808087\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:25:52Z","timestamp":1782793552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1808087\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":31,"alternative-id":["10.3389\/fmed.2026.1808087"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1808087","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"1808087"}}